The FTC ruled on April 3 that Illumina must divest itself of the cancer diagnostics firm Grail, a decision designed to promote competition in the multi-cancer early detection market by providing equal access to essential DNA sequencing technology.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/2159-8290.CD-NB2023-0029 | DOI Listing |
Publication Analysis
Top Keywords
antitrust order
4
order aimed
4
aimed equalizing
4
equalizing mced
4
mced field
4
field ftc
4
ftc ruled
4
ruled april
4
april illumina
4
illumina divest
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!